Pfizer, CDM clean up at Doctors' Choice

Professional ads for Pfizer's Chantix and Organon's NuvaRing were the year's top-rated as judged by physicians in the Association of Medical Media's fifth annual Doctors' Choice Awards.

The two-page Chantix ad, executed by Euro RSCG Life LM&P, was the top-scoring professional ad in the general practice category, while the one-page NuvaRing ad, by CommonHealth's Adient, took top honors in the specialty category.

The survey, which drew responses from 6,040 physicians, included 332 professional ads in 11 therapeutic categories among the 200 most widely advertised products for 2006.

Pfizer was the year's big winner with a total of five awards— for top scoring one- and two-page ads as well as the highest-ranked ads within the cardiovascular and anti-infective categories. Genentech/OSI, Merck and Organon each took home two awards.

On the agency side, Cline Davis & Mann was tops with four awards—three for Pfizer and one for Novo Nordisk's Novolog Flexpen—while AbelsonTaylor, Euro RSCG Life LM&P and CommonHealth's Adient each won two, respectively.

The awards were presented at a September 20 luncheon held at the New York Palace hotel in New York City.

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.